Nuclear medicine in cancer diagnosis

Nuclear medicine imaging has contributed significantly to diagnosis, treatment planning, and the evaluation of response to treatment in patients with cancer since the development of modern techniques in the 1970s. Diagnostic applications such as the bone scan continue to be the most common use in oncology because of their high sensitivity but the contribution of nuclear medicine to oncology can perhaps be best understood in the context of patient management. Staging of newly presenting cancer patients and restaging for treatment planning are reviewed here. For treatment response and disease recurrence nuclear medicine provides information non-invasively. The studies can be repeated with few side-effects and with low radiation absorbed doses. Results can be directly correlated with clinical laboratory data. The goals of biologically characterising an individual patient's tumour and predicting his or her response to treatment are within reach.

[1]  J S Fowler,et al.  Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. , 1982, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  O. Hoekstra,et al.  Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[4]  S. Hauptmann,et al.  F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. , 1994, Radiology.

[5]  M. Kaminski,et al.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.

[6]  G. Marchal,et al.  Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  T K Lewellen,et al.  Carbon-11-thymidine and FDG to measure therapy response. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  L E Williams,et al.  Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.

[9]  G. Denardo,et al.  Trials and tribulations: oncological antibody imaging comes to the fore. , 1997, Seminars in nuclear medicine.

[10]  T. Jones,et al.  Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. , 1995, European journal of cancer.

[11]  M. Sasaki,et al.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma , 1996, Annals of nuclear medicine.

[12]  A. Hendler,et al.  When to use bone scintigraphy. It can reveal things other studies cannot. , 1998, Postgraduate medicine.

[13]  L. Strauss,et al.  The relevance of positron emission tomography for the diagnosis and treatment of head and neck tumors. , 1993, The Journal of otolaryngology.

[14]  R. Hawkins,et al.  Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. , 1993, International journal of radiation oncology, biology, physics.

[15]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  G. V. von Schulthess,et al.  Detection of extrathoracic metastases by positron emission tomography in lung cancer. , 1998, The Annals of thoracic surgery.

[17]  M E Phelps,et al.  Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  B. Karlan,et al.  Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. , 1993, Gynecologic oncology.

[19]  T K Lewellen,et al.  Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.

[20]  E. Krenning,et al.  Somatostatin-receptor imaging in the localization of endocrine tumors. , 1990, The New England journal of medicine.

[21]  D. Mankoff,et al.  Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). , 1997, Nuclear medicine and biology.

[22]  J. Srigley,et al.  Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity , 1984 .

[23]  M. Berger,et al.  2-[C-11]thymidine imaging of malignant brain tumors. , 1999, Cancer research.

[24]  J. Hanke,et al.  Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  H. Minn,et al.  Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Otto Warburn,et al.  THE METABOLISM OF TUMORS , 1931 .

[27]  J. Sunderland,et al.  Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. , 1992, Radiology.

[28]  G van Kaick,et al.  Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  D Delbeke,et al.  Prospective investigation of positron emission tomography in lung nodules. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Mankoff,et al.  Quantitative [F-18]fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  W. Chapman,et al.  Staging recurrent metastatic colorectal carcinoma with PET. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  K L Lindsley,et al.  Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. , 1995, International journal of radiation oncology, biology, physics.

[33]  L. Goldman,et al.  Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. , 1979, The New England journal of medicine.

[34]  P. Gutin,et al.  Differentiation of Cerebral Radiation Necrosis from Tumor Recurrence by [18F]FDG and 82Rb Positron Emission Tomography , 1987, Journal of computer assisted tomography.

[35]  M. Mintun,et al.  Breast cancer: PET imaging of estrogen receptors. , 1988, Radiology.

[36]  R. Davis,et al.  In vivo detection and imaging of phosphatidylserine expression during programmed cell death. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Bernard Bendriem,et al.  In vivo imaging of oligonucleotides with positron emission tomography , 1998, Nature Medicine.

[38]  W L Ashburn,et al.  The flare phenomenon on radionuclide bone scan in metastatic prostate cancer. , 1984, AJR. American journal of roentgenology.

[39]  J S Fowler,et al.  A FLUORINATED GLUCOSE ANALOG, 2‐FLUORO-2‐DEOXY-D‐GLUCOSE (F‐18): NONTOXIC TRACER FOR RAPID TUMOR DETECTION , 1980, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  R Iwata,et al.  Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  T W Griffin,et al.  Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. , 1992, International journal of radiation oncology, biology, physics.